Table 1. Subgroup analyses of EGFR+ and ALK+ patients in large RCT with immune checkpoint inhibitors.
| Study | Treatment | Design | Number of EGFR + patients/ whole study population |
Number of ALK + patients/ whole study population |
HR (95% CI) EGFR+/HR (95% CI) whole study population (OS*) | HR ALK+/HR whole study population (OS) |
|---|---|---|---|---|---|---|
| Borghaei et al. (21) | Nivolumab vs. docetaxel | Phase 3 RCT, second line (non-squamous NSCLC) | Nivolumab arm: 44/292; docetaxel arm: 38/290 |
Nivolumab arm: 13/292; docetaxel arm: 8/290 |
1.18 (0.69–2.00)/0.75 (0.62–0.91) | NR (low number of patients) |
| Brahmer et al. (22) | Nivolumab vs. docetaxel | Phase 3 RCT, second line (squamous NSCLC) | – | – | – | – |
| Herbst et al. (23) | Pembrolizumab vs. docetaxel | Phase 2/3 RCT, second line, PD-L1+ (NSCLC) | Pembrolizumab arm: 60/690; docetaxel arm: 26/343 |
Pembrolizumab arm: 6/690; docetaxel arm: 2/343 |
0.88 (0.45–1.70)/0.67 (0.56–0.80) | NR (low number of patients) |
| Fehrenbacher et al. (33) | Atezolizumab vs. docetaxel | Phase 2 RCT, second line, (NSCLC) | Atezolizumab arm: 11/144; docetaxel arm: 8/143 |
Atezolizumab arm: 0/144; docetaxel arm: 3/143 |
NR | – |
| Rittmeyer et al. (24) | Atezolizumab vs. docetaxel | Phase 3 RCT, second line, (NSCLC) | Atezolizumab arm: 42/425; docetaxel arm: 43/425 |
Atezolizumab arm: 2/425; docetaxel arm: 0/425 |
1.24 (0.71-2.18)/0.73 (0.62–0.87) | – |
| Antonia et al. (34) | Durvalumab vs. placebo | Phase 3 RCT, consolidation after chemoradiotherapy, (stage 3 NSCLC) | Durvalumab arm: 29/476; placebo arm: 14/237 |
NR | 0.76 (0.35–1.64)/0.55 (0.45–0.68) (PFS) | NR |
*, when not mentioned otherwise in brackets, HR are referring to OS. RCT, randomized control trial; PFS, progression-free survival; OS, overall survival; NSCLC, non-small cell lung cancer; NR, not reported; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; PD-L1, programmed cell death ligand 1; HR, hazard ratio; CI, confidence interval.